Contribution: Industrial Research Assistance Program – Contributions to Firms
ME Therapeutics Inc.
$203,000.00
Monoclonal antibody to reverse tumor immunosuppression in cancer
FY 2017-18 · 2017-09-01
Summary
A monoclonal antibody to block tumor-associated immunosuppression by altering immune cell development will be developed in preparation for preclinical development and clinical trials.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
North Vancouver|North Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
837332592
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 1 | 2017-09-01 | 2017-18 | $194,000.00 |
| 3 | 2017-09-01 | 2017-18 | $203,000.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 16 days. The total amended value is 9,000 dollars.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 16 jours. La valeur totale des modifications est de 9 000 dollars.
Agreement End Date
2019-03-31
Agreement Number
892718
Agreement Start Date
2017-09-01
Agreement Title
Monoclonal antibody to reverse tumor immunosuppression in cancer
Agreement Title (French)
Anticorps monoclonal pour inverser l'immunosuppression tumorale dans le cancer
Agreement Type
Contribution
Agreement Value
$203,000.00
Amendment Date
2019-03-11
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
A monoclonal antibody to block tumor-associated immunosuppression by altering immune cell development will be developed in preparation for preclinical development and clinical trials.
Description (French)
Un anticorps monoclonal, destiné à bloquer l'immunosuppression associée à la tumeur en modifiant le développement des cellules immunitaires, sera élaboré en préparation du développement préclinique et des essais cliniques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
North Vancouver
Federal Riding (French)
North Vancouver
Federal Riding Number
59021
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
837332592
Recipient City
North Vancouver|North Vancouver
Recipient Country
CA
Recipient Legal Name
ME Therapeutics Inc.
Recipient Postal Code
V7L 4B4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q2-892718
